Sialidosis — a severe lysosomal storage disorder caused by biallelic pathogenic variants in NEU1 (Neuraminidase 1, also known as Sialidase 1) — produces a clinical spectrum that ranges from the relatively mild cherry-red spot myoclonus syndrome of Sialidosis Type I to the severe, dysmorphic, multi-system disease of Sialidosis Type II; NEU1 encodes the principal lysosomal neuraminidase that cleaves terminal sialic acid residues from the non-reducing ends of sialylated oligosaccharide chains on glycoproteins and glycolipids during intralysosomal catabolism, and NEU1 does not function as a monomeric enzyme but as part of a higher-order multienzyme complex — the protective protein/cathepsin A (PPCA) complex — assembled with beta-galactosidase and cathepsin A; NEU1 deficiency leads to the lysosomal accumulation of sialylated oligosaccharides and glycopeptides, which are excreted in urine as sialyloligosaccharides and can be detected by urine oligosaccharide analysis; the clinical spectrum divides into: (1) Sialidosis Type I — the mild allelic variant with onset in adolescence or young adulthood, characterized by the distinctive combination of cherry-red spots on fundoscopy, progressive myoclonic epilepsy (myoclonic jerks triggered by action and sensory stimulation, with or without generalized tonic-clonic seizures), largely preserved intellect, and no dysmorphic features — the cherry-red spot plus myoclonic epilepsy combination in an intellectually intact young person is pathognomonic for Sialidosis Type I; (2) Sialidosis Type II — the severe dysmorphic variant with onset ranging from in utero to infancy, producing a multi-system disease with coarse dysmorphic facies resembling mucopolysaccharidosis (gargoylism), skeletal dysplasia (dysostosis multiplex), organomegaly (hepatosplenomegaly), cardiac involvement, corneal clouding, cherry-red spots, progressive intellectual disability, severe neurological deterioration, and in its most severe neonatal form, non-immune hydrops fetalis and frequent perinatal or early-infant death; Sialidosis Type II is clinically and biochemically distinct from galactosialidosis — the condition caused by PPCA (CTSA gene) deficiency — which produces both NEU1 and beta-galactosidase deficiency due to PPCA's role in chaperoning and stabilizing the multienzyme complex; no approved enzyme replacement therapy (ERT) exists for sialidosis, and management is entirely supportive, with substrate reduction therapy and gene therapy approaches in early-stage preclinical or early clinical investigation.
Sialidosis Type II technology platforms — encompassing the metabolic medicine and lysosomal disease specialty platforms where the coarse dysmorphic features plus cherry-red spots plus myoclonic epilepsy combination triggers the diagnostic evaluation, the genetic testing platforms where NEU1 biallelic pathogenic variant identification provides molecular diagnosis and distinguishes sialidosis from galactosialidosis and the mucopolysaccharidoses it resembles clinically, the biochemical platforms performing urine oligosaccharide analysis and leukocyte or fibroblast NEU1 enzyme activity assay that provides the biochemical diagnosis, the cardiology and echocardiography platforms monitoring the cardiac involvement that may include valvular disease and cardiomyopathy, the hepatology and abdominal ultrasound platforms monitoring the progressive hepatosplenomegaly, the ophthalmology platforms monitoring the cherry-red spots and corneal clouding, the neurology and myoclonic epilepsy management platforms where progressive myoclonic epilepsy requires systematic anti-epileptic management (clonazepam, valproate, levetiracetam combinations), the Society for Mucopolysaccharide Diseases (MPS Society) and global lysosomal disease registry platforms coordinating multi-institution natural history data, and the palliative care coordination platforms where the severe Type II form — with its limited life expectancy particularly in the neonatal and congenital forms — requires early palliative care integration and advance care planning support — must maintain the availability and performance standards required by multi-organ surveillance across independent trajectories, progressive myoclonic epilepsy management, and early palliative care integration. This guide explains why Sialidosis Type II tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the multi-system disease burden, multi-organ surveillance intensity, myoclonic epilepsy management, and palliative care coordination obligations of modern care.
Why Sialidosis Type II Tech Platforms Require Specialized Monitoring Attention
Sialidosis Type II management is defined by several clinically severe challenges: the multi-organ simultaneous deterioration imperative — cardiac, hepatic, neurological, ophthalmologic, and skeletal systems all deteriorate on independent trajectories requiring separate monitoring programs that must be coordinated without any single system's surveillance preempting another's; the progressive myoclonic epilepsy management urgency — myoclonic jerks and generalized seizures progressing despite treatment are a primary cause of morbidity and a driver of functional decline, requiring systematic EEG-guided polypharmacy management; the early palliative care integration requirement — Sialidosis Type II, particularly in its severe neonatal form, has limited life expectancy, and early palliative care integration including advance care planning, feeding and respiratory support decision-making, and family support are clinical obligations that depend on reliable scheduling and documentation platform availability; and the diagnostic accuracy imperative — the MPS-like phenotype means Sialidosis Type II is frequently worked up through lysosomal storage and MPS panels where NEU1 enzyme assay and gene sequencing provide the molecular diagnosis.
NEU1 molecular genetic testing and enzyme assay platforms provide the diagnosis. Biallelic NEU1 pathogenic variants on gene sequencing combined with reduced or absent NEU1 enzyme activity in leukocytes or fibroblasts — with normal beta-galactosidase to exclude galactosialidosis — constitute the diagnostic standard. Monitor testing platforms at 1-minute intervals during laboratory hours.
Cardiac echocardiography scheduling platforms monitor a leading mortality risk. Valvular disease and cardiomyopathy in Sialidosis Type II progress on an independent timeline from neurological deterioration and require systematic echocardiography surveillance. Monitor cardiology scheduling platforms at 1-minute intervals during clinical hours.
Abdominal ultrasound platforms monitor hepatosplenomegaly progression. Liver and spleen volume increase on an independent trajectory and may cause complications including hypersplenism and coagulopathy. Monitor abdominal surveillance platforms at 1-minute intervals during clinical hours.
Progressive myoclonic epilepsy management platforms coordinate multi-drug seizure control. Clonazepam, valproate, and levetiracetam combination management with EEG at 6-month intervals requires uninterrupted platform availability. Monitor epilepsy management platforms at 1-minute intervals during clinical hours.
Palliative care coordination platforms integrate early-stage goals-of-care planning. Advance care planning, feeding and respiratory support decisions, and family bereavement support depend on reliable platform access. Monitor palliative care platforms at 1-minute intervals during clinical hours.
MPS Society and lysosomal disease registry platforms support research access. Multi-institution natural history data and clinical trial eligibility screening for substrate reduction and gene therapy approaches depend on registry platform availability. Monitor registry platforms at 1-minute intervals during operational hours.
What to Monitor on a Sialidosis Type II Tech Platform
NEU1 Molecular Genetic Testing and Enzyme Assay
Monitor NEU1 genetic testing referral records (clinical suspicion documentation — coarse facies with hepatosplenomegaly, cherry-red spots, and myoclonic epilepsy; non-immune hydrops fetalis with lysosomal storage suspected; MPS workup with normal MPS enzyme panel prompting oligosaccharidosis assessment), NEU1 gene sequencing records (full gene sequencing or lysosomal storage disorder panel identifying biallelic NEU1 pathogenic variants; compound heterozygous versus homozygous variant documentation; variant classification), NEU1 enzyme activity records (leukocyte or cultured fibroblast NEU1 neuraminidase activity assay — reduced activity confirming enzyme deficiency; simultaneous beta-galactosidase assay normal, distinguishing sialidosis from galactosialidosis; PPCA/cathepsin A activity documentation), urine oligosaccharide analysis records (urine oligosaccharide pattern consistent with sialyloligosaccharide accumulation — screening tool triggering lysosomal storage workup), galactosialidosis exclusion records (CTSA gene sequencing and PPCA enzyme activity — normal in sialidosis, reduced in galactosialidosis; the distinction changes the genetic counseling, as galactosialidosis involves a different gene), and prenatal and carrier testing records (family carrier testing; prenatal diagnosis via chorionic villus sampling or amniocentesis for biallelic NEU1 carrier couples) at 1-minute intervals during laboratory hours. Alert immediately — NEU1 enzyme assay platform failures during the diagnostic workup of a 6-month-old with coarse facies, progressive hepatosplenomegaly, corneal clouding, and cherry-red spots delay the enzymatic and molecular confirmation of lysosomal storage and the initiation of the multi-organ surveillance program that begins with confirmed Sialidosis Type II diagnosis.
Cardiac Surveillance — Echocardiography Scheduling
Monitor cardiology appointment scheduling records (echocardiography scheduling at baseline and annual or semi-annual intervals — valve morphology and function [mitral, aortic, tricuspid valve regurgitation or stenosis], ventricular wall thickness and function [cardiomyopathy assessment], pulmonary arterial pressure estimation, pericardial effusion assessment), echocardiography interpretation records (interval comparison to prior studies — valve function progression, cardiomyopathy development, chamber dilation; cardiac MRI scheduling where echocardiographic windows are limited), cardiac management records (cardiology follow-up scheduling for identified valve disease — medication initiation [diuretics, ACE inhibitors], surgical valve intervention planning for severe disease, arrhythmia monitoring), ECG and Holter monitoring records (arrhythmia surveillance for conduction disease), and cardiology-palliative care coordination records (advanced cardiac disease management integrated with overall goals of care — particularly relevant in Sialidosis Type II with multi-system deterioration) at 1-minute intervals during clinical hours. Alert immediately — echocardiography scheduling platform failures delay the 6-month cardiac reassessment for a 2-year-old with Sialidosis Type II who was found to have progressive mitral regurgitation on the prior study, where the current study determines whether the regurgitation severity has crossed the threshold requiring cardiology intervention planning.
Hepatic and Splenic Surveillance — Abdominal Ultrasound Scheduling
Monitor abdominal ultrasound scheduling records (liver and spleen ultrasound scheduling at 6-12 month intervals — liver volume estimation, spleen volume estimation, hepatic echotexture, portal flow assessment), laboratory surveillance records (complete blood count for hypersplenism detection — thrombocytopenia, neutropenia, anemia; liver function tests — AST, ALT, GGT, albumin, INR for hepatic synthetic function), gastroenterology referral records (portal hypertension evaluation scheduling for advanced hepatosplenomegaly — varices surveillance, ascites management), nutritional management records (dietitian referral scheduling for hepatomegaly-associated feeding difficulties; nasogastric or gastrostomy tube feeding initiation scheduling for progressive feeding dysfunction), and splenomegaly complication records (hypersplenism management — transfusion threshold documentation; antibiotic prophylaxis coordination for functional asplenia considerations) at 1-minute intervals during clinical hours.
Ophthalmology — Cherry-Red Spot and Corneal Monitoring
Monitor ophthalmology appointment scheduling records (ophthalmic examination scheduling at baseline and annual intervals — fundoscopy for cherry-red spot documentation and monitoring, slit-lamp examination for corneal clouding assessment, visual acuity testing, electroretinography if macular involvement is suspected), fundoscopy interpretation records (cherry-red spot size and clarity documentation — cherry-red spots in Sialidosis Type II may be present from infancy; interval comparison; correlation with neurological deterioration timeline), corneal clarity records (corneal clouding grade and visual impact documentation; contact lens or spectacle correction scheduling where corneal clouding limits visual acuity), low vision and visual rehabilitation records (low vision assessment scheduling for functionally significant visual impairment; orientation and mobility referral), and ophthalmology-palliative care coordination records (advanced visual impairment integrated with goals of care — visual support interventions proportionate to overall prognosis and goals) at 1-minute intervals during clinical hours.
Progressive Myoclonic Epilepsy Management
Monitor neurology visit scheduling records (epilepsy review scheduling at 3-6 month intervals — seizure frequency, myoclonus severity, medication adherence, side effect monitoring), EEG scheduling records (routine and prolonged EEG at 6-month intervals — progressive myoclonic epilepsy pattern characterization, background slowing, photosensitivity, cortical myoclonus correlates; EEG correlation with clinical myoclonus worsening), anti-epileptic medication management records (clonazepam, valproate, and levetiracetam combination documentation; dose adjustment scheduling; drug level monitoring; piracetam or zonisamide addition scheduling for refractory myoclonus), medication side effect surveillance records (valproate hepatotoxicity monitoring — LFTs with increased frequency given pre-existing hepatic disease from sialidosis; thrombocytopenia monitoring for valproate in the setting of hypersplenism), and myoclonus impact records (myoclonus frequency and functional impact documentation — activities of daily living, feeding, sleep, physical therapy participation all impacted by myoclonic severity) at 1-minute intervals during clinical hours.
Palliative Care Coordination and Advance Care Planning
Monitor palliative care referral records (early palliative care integration scheduling — palliative care consultation within the first year of diagnosis for Sialidosis Type II given limited life expectancy; goals of care discussion initiation; family and caregiver support), advance care planning records (advance directive scheduling and documentation — resuscitation preferences, mechanical ventilation preferences, artificial nutrition and hydration preferences, hospitalization preferences; documented discussions; periodic review and update scheduling), feeding and respiratory support records (nasogastric and gastrostomy tube feeding decision scheduling — shared decision-making with family; speech-language pathology swallowing assessment scheduling; respiratory support decision scheduling for progressive respiratory compromise from diaphragmatic weakness or aspiration), bereavement and family support records (family counseling scheduling; sibling support resources; anticipatory grief support; bereavement follow-up scheduling after patient death), and interdisciplinary case conference records (quarterly interdisciplinary case conference scheduling — integrating cardiology, hepatology, neurology, ophthalmology, nutrition, and palliative care updates into a unified plan) at 1-minute intervals during clinical hours. Alert immediately — palliative care platform failures disrupt the advance care planning appointment for the family of an 18-month-old with severe Sialidosis Type II who is beginning to show respiratory compromise, where the goals of care conversation about respiratory support preferences must be completed before an acute respiratory event forces an unplanned decision.
MPS Society and Lysosomal Disease Registry Platforms
Monitor lysosomal disease registry enrollment records (MPS Society and global lysosomal disease registry — NEU1 genotype, clinical phenotype, disease severity scores, multi-organ surveillance data, treatment responses, imaging data), natural history data submission records (serial multi-organ outcome data submission — cardiac, hepatic, neurological, ophthalmologic trajectories contributing to the global understanding of Sialidosis Type II natural history), clinical trial screening records (substrate reduction therapy trial eligibility — enrollment criteria, safety monitoring, outcome measure documentation; gene therapy investigational access where available), and family and community support records (MPS Society family network access, disease education, caregiver support resources, sibling and family counseling referrals) at 1-minute intervals during operational hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Sialidosis Type II management coordinates across metabolic medicine (diagnosis and coordination), cardiology (cardiac surveillance), hepatology (hepatic surveillance), neurology (myoclonic epilepsy), ophthalmology (cherry-red spot and corneal monitoring), nutrition and dietetics (feeding support), palliative care (goals of care), genetics (NEU1 diagnosis and family counseling), and international lysosomal disease registry coordination — authentication failures block every member of the multi-organ surveillance team.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, echocardiography scheduling systems, epilepsy management portals, ophthalmology coordination platforms, palliative care documentation systems, and MPS Society registry portals.
HIPAA and Ultra-Rare Disease Patient Privacy Considerations
Sialidosis Type II technology platforms handle highly sensitive PHI including NEU1 molecular genetic testing (biallelic recessive variants with implications for carrier parents and reproductive decision-making), progressive multi-organ deterioration documentation, advance care planning and end-of-life preference records, perinatal death records in the most severe neonatal form, and rare disease registry enrollment data. The combination of pediatric patient population, intellectual disability, and life-limiting prognosis creates heightened surrogate consent and guardian documentation requirements in addition to standard HIPAA obligations.
The biallelic recessive inheritance of Sialidosis Type II creates genetic information privacy obligations under GINA for both parents as obligate carriers, in addition to HIPAA Privacy and Security Rule requirements for the affected child's clinical records.
Alerting Strategy for Sialidosis Type II Tech Platforms
Immediate 24/7 alerting for palliative care and advance care planning platforms: Advance care planning documents must be accessible at all hours, including during acute hospitalizations and emergency presentations where goals of care documentation is immediately relevant.
Immediate clinical-hours alerting for cardiac echocardiography scheduling: Cardiac disease is a leading mortality risk in Sialidosis Type II and its surveillance scheduling cannot be disrupted.
Immediate clinical-hours alerting for progressive myoclonic epilepsy management platforms: EEG scheduling, polypharmacy management, and medication side effect monitoring require continuous platform availability.
Immediate clinical-hours alerting for hepatic and abdominal surveillance platforms: Hepatosplenomegaly with hypersplenism and portal hypertension complications require systematic monitoring.
Immediate laboratory-hours alerting for NEU1 genetic testing and enzyme assay platforms: Molecular and enzymatic diagnosis enables the multi-organ surveillance program to begin.
Immediate clinical-hours alerting for ophthalmology scheduling platforms: Cherry-red spot monitoring and corneal clouding surveillance are integral to multi-organ tracking.
Sustained-failure alert (10–15 minutes): MPS Society registry platforms, family support platforms, and research consortium portals.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms Sialidosis Type II platform availability from the geographies where metabolic medicine lysosomal disease centers, pediatric cardiology, and MPS Society registry programs concentrate.
Status Page for Sialidosis Type II Care Team Communication
A real-time status page gives metabolic medicine specialists coordinating multi-organ surveillance, pediatric cardiologists tracking valvular disease, pediatric neurologists managing myoclonic epilepsy, hepatologists monitoring hepatosplenomegaly, ophthalmologists tracking cherry-red spots, palliative care teams coordinating goals-of-care, and MPS Society registry coordinators immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in Sialidosis Type II care coordination documents, palliative care advance directive documentation, and NEU1 diagnostic laboratory contingency procedures.
Vigilmon Setup for Sialidosis Type II Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Advance care planning platform | 1 min | Slack + PagerDuty (24/7) | | NEU1 molecular genetic testing | 1 min | Slack + PagerDuty (lab hours) | | NEU1 enzyme activity assay | 1 min | Slack + PagerDuty (lab hours) | | Urine oligosaccharide analysis | 1 min | Slack + PagerDuty (lab hours) | | Cardiac echocardiography scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Cardiology follow-up and management | 1 min | Slack + PagerDuty (clinical hours) | | Abdominal ultrasound scheduling (liver/spleen) | 1 min | Slack + PagerDuty (clinical hours) | | Liver function and hematology surveillance | 1 min | Slack + PagerDuty (lab hours) | | Epilepsy visit and medication management | 1 min | Slack + PagerDuty (clinical hours) | | EEG scheduling (6-month intervals) | 1 min | Slack + PagerDuty (clinical hours) | | Ophthalmology and cherry-red spot monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Palliative care coordination | 1 min | Slack + PagerDuty (clinical hours) | | Feeding and respiratory support scheduling | 1 min | Slack + PagerDuty (clinical hours) | | MPS Society lysosomal disease registry | 2 min | Slack (business hours) | | Research and substrate reduction therapy access | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure advance care planning platform with 24/7 immediate alerting — highest-priority for this life-limiting condition
- Add NEU1 molecular genetic testing with immediate laboratory-hours alerting
- Configure NEU1 enzyme activity assay with immediate laboratory-hours alerting
- Add urine oligosaccharide analysis platforms with immediate laboratory-hours alerting
- Configure cardiac echocardiography scheduling with immediate clinical-hours alerting
- Add cardiology follow-up and management platforms with immediate clinical-hours alerting
- Configure abdominal ultrasound scheduling with immediate clinical-hours alerting
- Add liver function and hematology surveillance laboratory platforms with immediate laboratory-hours alerting
- Configure epilepsy visit and medication management with immediate clinical-hours alerting
- Add EEG scheduling platforms (6-month intervals) with immediate clinical-hours alerting
- Configure ophthalmology scheduling with immediate clinical-hours alerting
- Add palliative care coordination platforms with immediate clinical-hours alerting
- Configure feeding and respiratory support scheduling with immediate clinical-hours alerting
- Add MPS Society lysosomal disease registry with sustained-failure alerting during business hours
- Configure research and substrate reduction therapy access platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all genetic testing, cardiac, hepatic, epilepsy, ophthalmology, palliative care, and registry platforms
- Add the status page URL to Sialidosis Type II advance care planning documents, NEU1 diagnostic laboratory contingency procedures, and multi-organ care coordination materials
Conclusion
Sialidosis Type II technology platforms are embedded in clinical decisions where palliative care coordination platform availability for the family of a 16-month-old with severe Sialidosis Type II — who has progressive hepatosplenomegaly with thrombocytopenia, worsening mitral regurgitation on echocardiography, escalating myoclonic epilepsy requiring three anti-epileptic medications, and who over the past two months has shown increasing difficulty with feeding and the early signs of respiratory compromise — when the metabolic medicine team has arranged an urgent interdisciplinary family meeting to discuss the goals of care including the question of whether gastrostomy tube placement, ventilatory support initiation, and escalating cardiac medications are consistent with the family's goals and values for their child's remaining months — cannot be disrupted by palliative care documentation platform failures that prevent the advance directive from being completed and filed before the acute deterioration that may require the emergency medical team to act on preferences that were never formally documented, because for families navigating the terminal phase of a child's life-limiting lysosomal storage disease, the advance care planning documentation that captures their expressed preferences is not an administrative formality but the clinical instrument that ensures their child's end-of-life care reflects the values and choices they communicated when they had the time and capacity to communicate them thoughtfully; where cardiac echocardiography scheduling platform availability for a 2-year-old with Sialidosis Type II whose prior echocardiogram showed moderate mitral regurgitation with mildly dilated left ventricle — when the pediatric cardiologist has scheduled the 6-month follow-up echocardiogram to determine whether the regurgitation has progressed to severe, which would trigger a cardiology-palliative care shared decision-making discussion about whether surgical or catheter-based valve intervention is consistent with the child's overall prognosis and the family's previously documented goals — cannot be disrupted by scheduling platform failures that delay the echocardiogram on which the treatment escalation decision depends; and where EEG scheduling platform availability for an 18-month-old with Sialidosis Type II whose myoclonic epilepsy has been increasing in frequency despite a three-drug regimen — when the 6-month EEG must be scheduled to determine whether the increased myoclonus reflects true epileptic progression or a non-epileptic movement disorder exacerbated by increased ataxia, because the answer determines whether medication escalation or physical management adaptation is the appropriate next step — cannot be disrupted by scheduling platform failures that leave the treatment escalation decision without its primary diagnostic basis. An advance care planning platform unavailable when a family is preparing for their child's terminal phase, a cardiac echocardiography scheduling platform interrupted when mitral regurgitation severity determines treatment escalation, an EEG scheduling platform unavailable when myoclonus frequency increase demands diagnostic characterization — these are not IT incidents. They are clinical disruptions in the management of a multi-system lysosomal storage disorder whose cardiac, hepatic, neurological, and ophthalmologic trajectories each require continuous surveillance, and whose life-limiting prognosis in its severe form makes advance care planning platform availability a matter of dignity, autonomy, and the family's ability to ensure their child's care reflects their expressed wishes.
Uptime monitoring gives Sialidosis Type II tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to lysosomal disease specialty centers, pediatric cardiology programs, NEU1 molecular genetic testing laboratories, MPS Society registries, and compliance auditors that platform operational reliability matches the multi-organ surveillance intensity, progressive myoclonic epilepsy management complexity, and early palliative care integration obligations of modern Sialidosis Type II care.
Start monitoring your Sialidosis Type II care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #sialidosis #NEU1 #neuraminidase #sialidase #lysosomal #storage #PPCA #cathepsin #galactosialidosis #cherryredspot #myoclonic #epilepsy #hepatosplenomegaly #cardiomyopathy #corneal #hydrops #MPS #glycoprotein #palliativecare #advancecareplan #raredisease #HIPAA #healthtech #digitalhealth #uptime #sre